Literature DB >> 16048934

Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

Caroline M Kusuma1, John F Kokai-Kun.   

Abstract

Lysostaphin is an endopeptidase that cleaves the pentaglycine cross-bridges of the staphylococcal cell wall rapidly lysing the bacteria. Recently, lysostaphin has been examined for its potential to treat infections and to clear Staphylococcus aureus nasal colonization, requiring a reliable method for determining the lysostaphin susceptibility of strains of S. aureus. We compared four methods for determining the lysostaphin susceptibility of 57 strains of methicillin-sensitive S. aureus, methicillin-resistant S. aureus, vancomycin intermediately susceptible S. aureus (VISA), mupirocin-resistant S. aureus, and various defined genetic mutants of S. aureus. Three reference lysostaphin-resistant S. aureus variants were also included in the assays as negative controls. The assays examined included turbidity, MIC, minimum bactericidal concentration (MBC), and disk diffusion assays. All of the strains of S. aureus tested, including a VISA strain which had previously been reported to be lysostaphin resistant, were susceptible to lysostaphin by all four methods. The three reference lysostaphin-resistant variants were resistant by all four methods. The disk diffusion assay was the simplest method to differentiate lysostaphin-susceptible S. aureus strains from lysostaphin-resistant variants, while the MBC assay could be used as a follow-up assay if required. In the disk diffusion assay, all strains of S. aureus tested revealed zones of inhibition of >/=11 mm using a 50-microg lysostaphin disk, while the three reference lysostaphin-resistant S. aureus variants had no zones of inhibition. In MBC assays, concentrations of lysostaphin ranging from 0.16 microg/ml to 2.5 microg/ml were found to cause a 3 log or greater drop from the initial CFU of S. aureus within 30 min for all strains tested.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048934      PMCID: PMC1196283          DOI: 10.1128/AAC.49.8.3256-3263.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood.

Authors:  Christof von Eiff; John F Kokai-Kun; Karsten Becker; Georg Peters
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  LYSOSTAPHIN: ENZYMATIC MODE OF ACTION.

Authors:  H P BROWDER; W A ZYGMUNT; J R YOUNG; P A TAVORMINA
Journal:  Biochem Biophys Res Commun       Date:  1965-04-23       Impact factor: 3.575

3.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.

Authors:  R F Pfeltz; V K Singh; J L Schmidt; M A Batten; C S Baranyk; M J Nadakavukaren; R K Jayaswal; B J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

5.  Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.

Authors:  J J Dajcs; E B Hume; J M Moreau; A R Caballero; B M Cannon; R J O'Callaghan
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-05       Impact factor: 4.799

6.  Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model.

Authors:  John F Kokai-Kun; Scott M Walsh; Tanya Chanturiya; James J Mond
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

Review 8.  Staphylococcus aureus capsular polysaccharides.

Authors:  Katherine O'Riordan; Jean C Lee
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection.

Authors:  William J Weiss; Eileen Lenoy; Timothy Murphy; LuAnna Tardio; Pamela Burgio; Steven J Projan; Olaf Schneewind; Lefa Alksne
Journal:  J Antimicrob Chemother       Date:  2004-02-04       Impact factor: 5.790

10.  Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections.

Authors:  Christopher Weidenmaier; John F Kokai-Kun; Sascha A Kristian; Tanya Chanturiya; Hubert Kalbacher; Matthias Gross; Graeme Nicholson; Birgid Neumeister; James J Mond; Andreas Peschel
Journal:  Nat Med       Date:  2004-02-01       Impact factor: 53.440

View more
  36 in total

1.  Staphylococcal phage 2638A endolysin is lytic for Staphylococcus aureus and harbors an inter-lytic-domain secondary translational start site.

Authors:  Igor Abaev; Juli Foster-Frey; Olga Korobova; Nina Shishkova; Natalia Kiseleva; Pavel Kopylov; Sergey Pryamchuk; Mathias Schmelcher; Stephen C Becker; David M Donovan
Journal:  Appl Microbiol Biotechnol       Date:  2012-07-10       Impact factor: 4.813

2.  Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK.

Authors:  Soo Youn Jun; Gi Mo Jung; Jee-Soo Son; Seong Jun Yoon; Yun-Jaie Choi; Sang Hyeon Kang
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

3.  Electrostatic-Mediated Affinity Tuning of Lysostaphin Accelerates Bacterial Lysis Kinetics and Enhances In Vivo Efficacy.

Authors:  Hongliang Zhao; Susan Eszterhas; Jacob Furlon; Hao Cheng; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection.

Authors:  Mathias Schmelcher; Yang Shen; Daniel C Nelson; Marcel R Eugster; Fritz Eichenseher; Daniela C Hanke; Martin J Loessner; Shengli Dong; David G Pritchard; Jean C Lee; Stephen C Becker; Juli Foster-Frey; David M Donovan
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

5.  Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88 HydH5 virion-associated peptidoglycan hydrolase: fusions, deletions, and synergy with LysH5.

Authors:  Lorena Rodríguez-Rubio; Beatriz Martínez; Ana Rodríguez; David M Donovan; Pilar García
Journal:  Appl Environ Microbiol       Date:  2012-01-20       Impact factor: 4.792

6.  Gene and protein sequence optimization for high-level production of fully active and aglycosylated lysostaphin in Pichia pastoris.

Authors:  Hongliang Zhao; Kristina Blazanovic; Yoonjoo Choi; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Appl Environ Microbiol       Date:  2014-02-21       Impact factor: 4.792

7.  Staphylococcus haemolyticus prophage ΦSH2 endolysin relies on cysteine, histidine-dependent amidohydrolases/peptidases activity for lysis 'from without'.

Authors:  Mathias Schmelcher; Olga Korobova; Nina Schischkova; Natalia Kiseleva; Paul Kopylov; Sergey Pryamchuk; David M Donovan; Igor Abaev
Journal:  J Biotechnol       Date:  2012-09-28       Impact factor: 3.307

Review 8.  Bacteriophage endolysins as novel antimicrobials.

Authors:  Mathias Schmelcher; David M Donovan; Martin J Loessner
Journal:  Future Microbiol       Date:  2012-10       Impact factor: 3.165

9.  Hydrogen/deuterium exchange mass spectrometry and site-directed disulfide cross-linking suggest an important dynamic interface between the two lysostaphin domains.

Authors:  Hai-Rong Lu; Mei-Gang Gu; Qiang Huang; Jin-jiang Huang; Wan-Ying Lu; Hong Lu; Qing-Shan Huang
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

10.  Wall teichoic acid deficiency in Staphylococcus aureus confers selective resistance to mammalian group IIA phospholipase A(2) and human beta-defensin 3.

Authors:  Tomaz Koprivnjak; Christopher Weidenmaier; Andreas Peschel; Jerrold P Weiss
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.